How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.com
Phase 3 Trial of 177Lu-PSMA I&T versus Hormone Therapy in Patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
Description:
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Sponsor:
CuriumPhase:
Phase 3
Contacts:
Darcy Denner, Ph.D. (Clinical Trial Director)darcy.denner@curiumpharma.com
Government Study Link:
NCT05204927 - Click here to see study onClinicalTrials.gov
Inclusion
- Males, 18 years or older
- Positive PSMA PET scan
- Proven metastatic castration-resistant prostate cancer
Exclusion
- Previous treatment with chemotherapy in the castration-resistant setting
- Previous treatment with more than one ARAT
- Previous treatment with other radioligand therapy
Patient Education
Publications
Publications Not Yet Provided
Locations
Loading...
Share your feedback
Help us improve your experience